Division of Urologic Surgery, Department of Surgery, and Duke Prostate Center, Duke University School of Medicine, Durham, NC 27710, USA.
BJU Int. 2010 Jun;105(12):1654-9. doi: 10.1111/j.1464-410X.2009.09060.x. Epub 2009 Nov 13.
To re-calibrate the previously published Duke Prostate Center (DPC) nomogram for the prediction of biochemical recurrence (BCR) after radical prostatectomy (RP) to not only predict overall BCR but also the clinically more relevant endpoint of an aggressive recurrence (i.e. a BCR with a postoperative PSA doubling time (PSADT) of <9 months).
Using the established point-scale system based upon the previously published DPC nomogram, we re-calibrated this point system to predict not just BCR, but also aggressive BCR within 2599 men treated with RP from the DPC database. PSADT was computed on all patients meeting the recurrence definition who had a minimum of two PSA values, separated by at least 3 months, and < or =2 years after recurrence. External validation was performed using data from 1695 men treated with RP within the Shared Equal Access Regional Cancer Hospital (SEARCH) database by calculating the concordance index c and by plotting calibration curves.
The median follow-up for patients with no BCR was 56 and 47 months for DPC and SEARCH, respectively. In the DPC modelling cohort and the SEARCH validation cohort, 645 (25%) and 557 (33%) men had BCR, while 83 (3.2%) and 71 (4.2%) patients had an aggressive recurrence. In external validation, predictive accuracy for an aggressive BCR was high (c = 0.83) and the nomogram showed good calibration.
We re-calibrated an existing nomogram to not only predict overall BCR after RP but also aggressive recurrence after RP. Our new tool can provide valuable information for patient counselling and patient selection for adjuvant therapy trials.
重新校准先前发表的杜克前列腺中心(DPC)列线图,以预测根治性前列腺切除术(RP)后生化复发(BCR),不仅预测总体 BCR,还预测更具临床相关性的侵袭性复发(即术后 PSA 倍增时间(PSADT)<9 个月的 BCR)。
使用先前发表的 DPC 列线图的既定评分系统,我们重新校准了该评分系统,以预测不仅是 BCR,还预测在 DPC 数据库中接受 RP 治疗的 2599 名男性中的侵袭性 BCR。在符合复发定义且至少有两次 PSA 值的所有患者中计算 PSADT,两次 PSA 值之间至少相隔 3 个月,且在复发后 <或=2 年内。通过计算一致性指数 c 和绘制校准曲线,使用来自接受 RP 治疗的 1695 名男性的共享平等获取区域癌症医院(SEARCH)数据库中的数据进行外部验证。
无 BCR 的患者中位随访时间分别为 DPC 和 SEARCH 的 56 个月和 47 个月。在 DPC 建模队列和 SEARCH 验证队列中,645(25%)和 557(33%)名男性发生 BCR,而 83(3.2%)和 71(4.2%)名患者发生侵袭性复发。在外部验证中,对侵袭性 BCR 的预测准确性较高(c=0.83),且列线图显示出良好的校准。
我们重新校准了现有的列线图,不仅可以预测 RP 后的总体 BCR,还可以预测 RP 后的侵袭性复发。我们的新工具可以为患者咨询和辅助治疗试验的患者选择提供有价值的信息。